CytoReason vs Pepticom
CytoReason vs Pepticom, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and Pepticom on 55/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 55/100
- domain rating: 40/100 against 24/100
- headcount: 116 against 16
- headcount growth: +13.7% against -1.8%
- funding raised: $128M against $7.6M
- LinkedIn following: 12,830 against 3,160
Pepticom
Leads on none of the measures we hold for both companies.
At a glance
| Measure | CytoReason | Pepticom |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | AI platform for accelerating novel peptide therapeutic discovery and development. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Drug Discovery, Clinical Development, Peptide Drugs |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2016 | 2011 |
| Headquarters | Tel Aviv, Israel | Jerusalem, Israel |
| Status | Active | Inactive |
Size, funding and growth
| Measure | CytoReason | Pepticom |
|---|---|---|
| Employees | 116 | 16 |
| Headcount growthLast 12 months | +13.7% | -1.8% |
| Total funding | $128M | $7.6M |
| Latest round | Series B | Funding Round |
| LinkedIn followers | 12,830 | 3,160 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | Pepticom |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 55/100 |
| Traction | 60/100 | 47/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 30/100 | 33/100 |
| Quality | 78/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | F (21/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 24/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | Pepticom |
|---|---|---|
| Hosting | Not detected | Self Managed |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Segment | Google Analytics 4, Google Tag Manager |
CytoReason vs Pepticom: common questions
Which is better, CytoReason or Pepticom?
On our 0-100 score CytoReason rates higher (68/100 against 55/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do CytoReason and Pepticom compare on the numbers?
CytoReason leads on our overall score (68/100 against 55/100), domain rating (40/100 against 24/100), headcount (116 against 16), headcount growth (+13.7% against -1.8%), funding raised ($128M against $7.6M), LinkedIn following (12,830 against 3,160).
Read the full CytoReason review and pricing or the Pepticom review and pricing. You can also browse other CytoReason alternatives we track.